Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
